SAN JOSE, Calif., March 4, 2021 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer and infectious diseases,
announced today that the European Patent Office has issued the
first European patent for Anixa's novel CAR-T cancer treatment
technology, which has been licensed from The Wistar Institute and
is being developed in partnership with Moffitt Cancer Center.
The patent is titled, "METHODS AND COMPOSITIONS FOR TREATING
CANCER," and the inventors are Drs. Jose
Conejo-Garcia and Alfredo
Perales-Puchalt, both formerly of The Wistar Institute. Dr.
Conejo-Garcia is currently Chair of the Department of Immunology at
Moffitt Cancer Center and Dr. Alfredo
Perales-Puchalt is currently Vice President of R&D at
Geneos Therapeutics. The patent is assigned to The Wistar Institute
and Anixa Biosciences' majority-owned subsidiary, Certainty
Therapeutics, Inc., which is the exclusive, world-wide
licensee.
Dr. Amit Kumar, President and CEO
of Anixa Biosciences, stated, "We are pleased that the European
Patent Office (EPO) has issued this patent. This patent will
provide protection of our technology throughout the European Union,
in addition to the existing protection from our issued patent in
the United States. Our CAR-T
cancer technology takes advantage of specific hormone–hormone
receptor biology to address malignancies and may hold promise to be
the first successful CAR-T therapy against solid tumors.
While our initial focus is the treatment of ovarian cancer,
the technology is broad and may also be effective in treating other
solid tumors by exploiting an anti-angiogenesis mechanism of
action."
Heather A. Steinman, PhD, MBA,
Vice President of Business Development at The Wistar Institute
said, "Issuance of this European patent along with the previously
issued U.S. patent is a critical step in the advancement of our
CAR-T technology, which has been exclusively licensed to Anixa's
subsidiary, Certainty Therapeutics, Inc. As a collaborator of
and minority shareholder in Certainty, we support the continuing
advancement of this novel, targeted immunotherapy into the clinic
where we hope one day it may help provide alternative treatment
choices for ovarian and other cancer patients."
Dr. Kumar continued, "We are expecting to file an IND
application for our ovarian cancer CAR-T therapy by the end of the
first calendar quarter of 2021. After we receive clearance from the
FDA, we will begin the clinical studies at Moffitt Cancer
Center."
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company developing a number of
programs addressing cancer and infectious disease. Anixa's
therapeutics portfolio includes a cancer immunotherapy program
which uses a novel type of CAR-T, known as chimeric endocrine
receptor T-cell (CER-T) technology, and a Covid-19 therapeutics
program focused on inhibiting certain viral protein function. The
company's vaccine portfolio includes a vaccine to prevent breast
cancer, and specifically triple negative breast cancer (TNBC), the
most deadly form of the disease, and a vaccine to prevent ovarian
cancer. These vaccine technologies focus on immunizing against
specific proteins that have been found to be expressed in certain
forms of cancer. Anixa continually examines emerging technologies
in complementary fields for further development and
commercialization. Additional information is available at
www.anixa.com.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect Anixa's current expectations
concerning future events and results. We generally use the words
"believes," "expects," "intends," "plans," "anticipates," "likely,"
"will" and similar expressions to identify forward-looking
statements. Such forward-looking statements, including those
concerning our expectations, involve risks, uncertainties and other
factors, some of which are beyond our control, which may cause our
actual results, performance or achievements, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Investor contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Media contact:
Sherry Ash
anixapress@gmail.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-european-patent-issued-for-its-car-t-cancer-therapy-301240422.html
SOURCE Anixa Biosciences, Inc.